Cellectis(CLLS) - 2023 Q1 - Quarterly Report
Cellectis(CLLS)2023-03-08 00:00
EXHIBIT 99.1 Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented in a Live Webcast; First patient dosed with UCART22 produc ...